Brief Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Intervention / Treatment
- Drug: INCB161734
- Drug: Cetuximab
- Drug: Retifanlimab
- Drug: GEMNabP
- Drug: mFOLFIRINOX
- Drug: FOLFOX
- Drug: FOLFIRI
- Drug: INCA33890
Inclusion Criteria:
- ≥18 years old.
- Locally advancedat a late stage, far along or metastatic solid tumor with KRAS G12D mutation.
- For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome.
- Cohort specific requirements aas defined in the protocol.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1.